What are Fenofibric Acid EC Pellets 37.77% W/W?

Fenofibric Acid EC Pellets 37.77% W/W are pharmaceutical pellets specified to contain fenofibric acid at a drug loading of 37.77% w/w. Fenofibric acid is a lipid-modifying active ingredient used in certain finished medicines to help manage elevated triglyceride and cholesterol levels. The EC designation generally refers to enteric coating; the precise coating system and release characteristics should be confirmed from supplier documentation.

Uses / Applications

Fenofibric acid is used in finished medicines to help manage certain lipid disorders, including elevated triglyceride levels and mixed dyslipidaemia, according to the approved product information.

Potential applications of fenofibric acid pellets include:

• Pharmaceutical formulation development.

• Use as an intermediate in suitable oral dosage forms.

• Further processing by qualified pharmaceutical manufacturers.

• Development of formulations requiring specified enteric protection, where supported by the product specification.

The suitability of these pellets for a specific finished dosage form must be confirmed through supplier documentation and formulation assessment.

6. Benefits

• Specified drug loading: Identified as 37.77% w/w fenofibric acid.

• Pellet-based intermediate: Intended for further pharmaceutical processing, subject to technical suitability.

• Enteric-coated designation: EC indicates an enteric-coated product; the actual coating system requires confirmation.

• Technical documentation: Product-specific specifications may be requested from the supplier.

• Sourcing support: Kelar Pharmachem India supports pharmaceutical sourcing and export requirements.

Actual product performance depends on composition, coating characteristics, manufacturing conditions, and applicable quality specifications.

7. Side Effects

Fenofibric acid-containing finished medicines may cause side effects such as:

• Abdominal discomfort

• Nausea

• Headache

• Back pain

• Changes in liver enzyme levels

More serious adverse effects, including muscle-related problems and liver injury, may occur in some patients. The approved prescribing information should be consulted for a complete safety profile and monitoring recommendations.

These effects relate to the active ingredient in a finished medicine and should not be interpreted as instructions for direct use of the pharmaceutical pellets.

8. How Does It Work?

Fenofibric acid activates peroxisome proliferator-activated receptor alpha (PPARα), which influences lipid metabolism. This can increase the breakdown and clearance of triglyceride-rich particles and affect levels of triglycerides and other circulating lipids.

The EC designation generally indicates an enteric-coated formulation intended to provide protection under acidic gastric conditions. The exact coating system, dissolution behaviour, and release profile of these pellets must be verified through supplier documentation and relevant quality-control data.

9. Dosage Guidelines / Processing Instructions

These pellets are pharmaceutical intermediates and should not be assumed suitable for direct administration.

• Confirm the 37.77% w/w drug-loading specification and assay basis.

• Verify the enteric-coating composition and intended release characteristics.

• Assess compatibility with excipients and the intended finished dosage form.

• Evaluate content uniformity, dissolution, stability, and other applicable quality attributes.

• Follow validated manufacturing procedures and applicable quality-control requirements.

The dose and treatment duration of a finished fenofibric acid medicine must follow its approved product information and the recommendation of a qualified healthcare professional.

10. When Not to Use

For the finished medicine, fenofibric acid may be contraindicated in individuals with known hypersensitivity to the active ingredient or relevant formulation components, severe renal impairment, active liver disease, or gallbladder disease, depending on the approved product information.

For manufacturing purposes, do not use the pellets if their identity, composition, quality status, storage history, or suitability for the intended application cannot be verified.

11. Drug / Product Interactions

Fenofibric acid-containing medicines may interact with anticoagulants, statins, immunosuppressants, and other medicines, depending on the product and patient circumstances. Some combinations may increase the risk of muscle injury or require additional monitoring.

For formulation development, assess compatibility with other active ingredients, excipients, coating materials, and processing conditions. Do not assume compatibility without supporting technical data.

12. Safety Advice

• Handle the pellets according to supplier documentation and applicable site procedures.

• Apply appropriate protective measures based on the material safety assessment.

• Avoid generating or inhaling dust during handling, where applicable.

• Maintain batch identification and traceability.

• Review available technical and safety documentation before processing.

• Ensure the finished product meets the quality and regulatory requirements applicable to its intended market.

13. General Instructions

• Verify the active ingredient and 37.77% w/w loading against batch documentation.

• Confirm the EC designation and release profile with the supplier.

• Use the pellets only within an appropriate pharmaceutical manufacturing process.

• Assess coating integrity, stability, and compatibility during formulation development.

• Maintain suitable quality-control records.

• Request additional technical documentation where required.

14. Special Dietary / Lifestyle Tips

Lifestyle advice applies to patients using a finished fenofibric acid medicine, not to the pellets themselves.

Patients managing lipid disorders may be advised by their healthcare professional to follow an appropriate diet, maintain regular physical activity, and attend recommended monitoring appointments. Lifestyle measures should complement, not replace, prescribed treatment.

15. Comparison with Other Formulations

These formulations are not automatically interchangeable. Selection depends on the target dosage form, approved specifications, release performance, and manufacturing requirements.

16. Precautions & Warnings

• Confirm the 37.77% w/w drug-loading basis with the supplier.

• Verify the enteric-coating system and release characteristics.

• Do not assume a specific coating polymer, pellet size, or dissolution profile without documentation.

• Evaluate stability and compatibility under intended processing conditions.

• Confirm suitability for the intended finished dosage form and destination market.

• Avoid unverified claims about regulatory approvals, certifications, or manufacturing compliance.

17. Can I Use It With Other Medicines or Ingredients?

For pharmaceutical manufacturing, these pellets may be considered for use with other ingredients only after an appropriate compatibility and formulation assessment. Evaluation should cover chemical stability, physical properties, coating integrity, processing behaviour, and the intended release profile.

For patient treatment, only an appropriately manufactured finished medicine should be used according to its approved product information and professional guidance. The pellets should not be mixed with medicines for self-administration.

18. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

19. FAQs

Q1. What are Fenofibric Acid EC Pellets 37.77% W/W?

They are pharmaceutical pellets specified to contain fenofibric acid at a drug loading of 37.77% w/w.

Q2. What does 37.77% w/w mean?

It indicates a stated weight-by-weight proportion of 37.77% fenofibric acid. The assay basis should be confirmed against the supplier’s specification.

Q3. What does EC mean?

EC generally stands for enteric-coated. The exact coating composition and release characteristics should be confirmed through technical documentation.

Q4. What is fenofibric acid used for?

Fenofibric acid is used in certain finished medicines to manage specific lipid disorders, according to the approved product information.

Q5. Are these pellets a finished medicine?

The product name identifies pharmaceutical pellets, not a finished patient-ready dosage form. The intended application should be confirmed with the supplier.

Q6. Is technical documentation available?

Technical data sheets and additional product specifications are available upon request, subject to supplier availability.

Q7. What packing options are available?

Packing details are available on request and should be confirmed with the supplier.

Q8. Can these pellets be used in any oral formulation?

No. Suitability depends on the pellet specifications, coating characteristics, formulation compatibility, and requirements of the intended finished dosage form.